Back to Search
Start Over
5-Nitro-3-(2-(4-phenylthiazol-2-yl)hydrazineylidene)indolin-2-one derivatives inhibit HIV-1 replication by a multitarget mechanism of action.
- Source :
-
Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2023 Jun 23; Vol. 13, pp. 1193280. Date of Electronic Publication: 2023 Jun 23 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- In the effort to identify and develop new HIV-1 inhibitors endowed with innovative mechanisms, we focused our attention on the possibility to target more than one viral encoded enzymatic function with a single molecule. In this respect, we have previously identified by virtual screening a new indolinone-based scaffold for dual allosteric inhibitors targeting both reverse transcriptase-associated functions: polymerase and RNase H. Pursuing with the structural optimization of these dual inhibitors, we synthesized a series of 35 new 3-[2-(4-aryl-1,3-thiazol-2-ylidene)hydrazin-1-ylidene]1-indol-2-one and 3-[3-methyl-4-arylthiazol-2-ylidene)hydrazine-1-ylidene)indolin-2-one derivatives, which maintain their dual inhibitory activity in the low micromolar range. Interestingly, compounds 1a, 3a, 10a, and 9b are able to block HIV-1 replication with EC <subscript>50</subscript> < 20 µM. Mechanism of action studies showed that such compounds could block HIV-1 integrase. In particular, compound 10a is the most promising for further multitarget compound development.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Corona, Meleddu, Delelis, Subra, Cottiglia, Esposito, Distinto, Maccioni and Tramontano.)
Details
- Language :
- English
- ISSN :
- 2235-2988
- Volume :
- 13
- Database :
- MEDLINE
- Journal :
- Frontiers in cellular and infection microbiology
- Publication Type :
- Academic Journal
- Accession number :
- 37424782
- Full Text :
- https://doi.org/10.3389/fcimb.2023.1193280